Pharma 101 /Regulation
cGMP, GCP, GLP, GCLP, GDP, GDocP, GVP — the "x" changes, the expectation doesn't. Here's what each one means and who it applies to.
The formula
The "x" is a placeholder for the activity being regulated — Manufacturing, Clinical, Laboratory, Distribution, and so on. Every GxP standard is enforced by regulatory authorities (FDA, EMA, MHRA, PMDA). Many of them are harmonised through ICH guidelines, but it is the regulators — not ICH — that inspect, cite, and enforce. Failure in any one of them can halt a trial, shut down a site, or block a drug from patients.
The standards
Each standard governs a different activity — but all share the same philosophy: do it right, write it down, prove it.
FDA 21 CFR Parts 210/211 · EudraLex Volume 4, Parts I & II and Annexes
Governs how pharmaceutical drugs are manufactured, tested, and quality-assured before release. The "c" means current — manufacturers must use up-to-date technology and methods, not just what was acceptable at time of approval.
ICH E6(R2) / E6(R3) · FDA 21 CFR Parts 50, 56, 312 & Part 11
The international ethical and scientific quality standard for designing, conducting, recording, and reporting clinical trials. Protects the rights, safety, and welfare of human subjects, while ensuring trial data are credible and accurate.
OECD GLP Principles · FDA 21 CFR Part 58 · EU Directive 2004/10/EC
Governs the planning, conducting, monitoring, recording, archiving, and reporting of non-clinical (animal and in-vitro) safety studies. Ensures that the data submitted to regulators to support human trials are reliable and reproducible.
WHO GCLP Guidelines · RQA/BARQA industry framework
An industry quality framework (not a standalone regulation) that bridges GLP and GCP. It applies to laboratories that analyze clinical trial samples — PK/PD, biomarker, and immunogenicity assays — and provides the standards needed to meet GCP and GLP expectations in a clinical lab setting.
EU GDP Guidelines 2013/C 343/01 · WHO GDP
Governs the storage and distribution of medicinal products from manufacturer to point of dispensing. A drug that is manufactured correctly but stored or shipped incorrectly can degrade — GDP ensures it arrives at the patient in the same condition it left the plant.
Applies across all GxPs — see also ALCOA++
The documentation rules that underpin every other GxP. If it wasn't written down, it didn't happen. Full guide →
EMA GVP Modules · FDA 21 CFR 314.80 / 600.80
Post-authorisation safety monitoring. Once a drug is approved, every adverse event must be collected, assessed, and reported. Clinical trial safety reporting during development is governed by GCP (ICH E2A); GVP takes over at approval and applies for the entire commercial life of the product.
Multiple standards can apply to the same team or activity simultaneously.
| Activity / Function | cGMP | GCP | GLP | GCLP | GDP | GVP |
|---|---|---|---|---|---|---|
| Drug manufacturing / CMO | — | — | — | — | — | |
| Non-clinical tox / safety studies | — | — | — | — | — | |
| Phase I–III clinical trials | — | — | — | — | ||
| Bioanalytical / PK lab | — | — | — | — | — | |
| Wholesaler / 3PL logistics | — | — | — | — | — | |
| Post-market safety (marketed drug) | — | — | — | — | — | |
| QC lab releasing drug batches | — | — | — | — | — | |
| CDMO (drug + logistics) | — | — | — | — |
They stack
A CDMO that manufactures and ships is subject to both cGMP and GDP simultaneously. A sponsor running a Phase IV study of their own approved product faces both GCP (trial conduct) and GVP (post-market safety reporting) obligations at the same time.
They vary by region
The FDA, EMA, MHRA, and PMDA each issue their own GxP regulations. ICH guidelines harmonise many of them — but not all. Always check the specific market's requirements.
GDocP runs through all of them
No matter which GxP applies, the documentation standard is the same: ALCOA++. Attributable, Legible, Contemporaneous, Original, Accurate — and complete, consistent, enduring, available.
Sources & further reading
GxP requirements are implemented by regulators and local quality systems. These official sources provide the context behind the standards summarized above.
BioCircuit covers regulatory updates, GxP enforcement actions, and the science behind drug development — delivered every Monday.